Get the Stockscreener App
167.35
1.36%
2.24
After Hours:
168.91
1.56
+0.93%
Neurocrine Biosciences Inc stock is traded at $167.35, with a volume of 1.30M.
It is up +1.36% in the last 24 hours and up +24.82% over the past month.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
See More
Previous Close:
$165.11
Open:
$165.23
24h Volume:
1.30M
Relative Volume:
1.12
Market Cap:
$16.83B
Revenue:
$3.10B
Net Income/Loss:
$668.60M
P/E Ratio:
25.73
EPS:
6.5044
Net Cash Flow:
$831.30M
1W Performance:
+7.01%
1M Performance:
+24.82%
6M Performance:
+8.85%
1Y Performance:
+34.40%
1-Day Range:
$164.52
$169.57
1-Week Range:
$154.06
$169.57
52-Week Range:
$122.14
$169.57
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
167.35 | 16.60B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
15.45 | 47.49B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.43 | 38.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.96 | 38.57B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.52 | 32.53B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.69 | 23.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX) - Yahoo Finance
A Look At Neurocrine Biosciences (NBIX) Valuation As New CRENESSITY Data Heads To ENDO 2026 - simplywall.st
Neurocrine publishes dosing guidelines for CAH treatment drug - Investing.com
Neurocrine to acquire Soleno Therapeutics for $2.9 billion By Investing.com - Investing.com Australia
Neurocrine Biosciences shares jump on fresh long-term CRENESSITY data catalyst - Quiver Quantitative
NBIX Stock Draws Bullish Targets After Soleno Deal - StocksToTrade
Neurocrine Biosciences Jumps 5.8% Amid Sector-Wide Rally - AlphaStreet
Neurocrine to present two-year Crenessity data at ENDO 2026 - Investing.com
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026 - PR Newswire
Goldman Sachs Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $213 - Moomoo
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Peter Lynch GARP Opportunity with Strong Growth and a PEG Ratio of 0.82 - ChartMill
Neurocrine Biosciences CSO Jude Onyia sells $1.76m in stock - Investing.com UK
Neurocrine Biosciences chief regulatory officer sells $354,321 in stock By Investing.com - Investing.com Canada
Neurocrine Biosciences CSO Jude Onyia sells $1.76m in stock By Investing.com - Investing.com Nigeria
Neurocrine Biosciences chief regulatory officer sells $354,321 in stock - Investing.com
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Neurocrine (NASDAQ: NBIX) CRO sells 2,261 shares after option exercise - Stock Titan
24,965-share Rule 144 sale notice for Neurocrine (NASDAQ: NBIX) - Stock Titan
Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating By Investing.com - Investing.com South Africa
Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating - Investing.com
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Form 144: 11,000-share sale notice tied to option exercise (NBIX) - Stock Titan
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 21% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Neurocrine Biosciences CSO Jude Onyia sells $1.71m in shares By Investing.com - Investing.com Australia
Neurocrine Biosciences CSO Jude Onyia sells $1.71m in shares - Investing.com UK
Neurocrine (NBIX) director Kevin Gorman receives grant of 5,248 stock options - Stock Titan
Neurocrine (NASDAQ: NBIX) CSO exercises options, sells 11,000 pre-planned shares - Stock Titan
NBIX (NBIX) director Richard Pops granted 2,567 Restricted Stock Units - Stock Titan
Neurocrine (NBIX) director granted stock options and RSUs as equity compensation - Stock Titan
Neurocrine Biosciences (NBIX) director receives 2,567 restricted stock units - Stock Titan
Director at Neurocrine (NASDAQ: NBIX) receives 2,567 RSUs as award - Stock Titan
Neurocrine (NBIX) director Stephen Sherwin receives 2,567 RSU equity grant - Stock Titan
Director at Neurocrine Biosciences (NASDAQ: NBIX) granted 2,567 RSUs - Stock Titan
Neurocrine (NASDAQ: NBIX) awards director 2,567 RSUs vesting in 2027 - Stock Titan
Neurocrine (NASDAQ: NBIX) grants options and RSUs to director - Stock Titan
RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $183 - Moomoo
Neurocrine Biosciences Should See More Upside on Crenessity Growth, RBC Says - Moomoo
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Data And Analyst Coverage - Sahm
RBC Lifts Price Target on Neurocrine Biosciences to $183 From $180, Keeps Outperform Rating - Moomoo
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and Bull Flag Breakout Setup - ChartMill
Neurocrine Biosciences’ David Boyer sells $609k in NBIX stock By Investing.com - Investing.com India
Neurocrine Biosciences’ David Boyer sells $609k in NBIX stock - Investing.com
Neurocrine (NBIX) executive sells 3,888 shares in pre-set 10b5-1 trade - Stock Titan
Neurocrine Biosciences (NBIX) 2026 meeting backs directors, pay and equity plan - Stock Titan
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
New Real‑World INGREZZA Data in Mild TD Might Change The Case For Investing In Neurocrine Biosciences (NBIX) - simplywall.st
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.19%
6.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):